{"id":"NCT04537793","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","officialTitle":"A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Through 5 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-19","primaryCompletion":"2022-06-03","completion":"2022-06-03","firstPosted":"2020-09-03","resultsPosted":"2023-06-28","lastUpdate":"2023-06-28"},"enrollment":83,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"Part A: ELX/TEZ/IVA","type":"EXPERIMENTAL"},{"label":"Part B: ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects 2 through 5 years of age.","primaryOutcome":{"measure":"Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites","timeFrame":"From Day 1 through Day 15","effectByArm":[{"arm":"Part A: ELX/TEZ/IVA","deltaMin":0,"sd":0}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":22,"countries":["United States","Australia","Canada","Germany","United Kingdom"]},"refs":{"pmids":["37983082","36921081","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Cough","Rhinorrhoea","Pyrexia","Vomiting","COVID-19"]}}